Ipilimumab Safety Profile: Associated with a high
Post# of 155339
(Total Views: 373)
Posted On: 07/23/2025 4:01:10 AM
Re: USS JOHNSTON #155329
Quote:
Ipilimumab Safety Profile:
Associated with a higher risk of immune-related adverse events (irAEs) compared to other immune checkpoint inhibitors.
Common side effects include:
Diarrhea
Rash
Fatigue
Nausea and vomiting
Abdominal pain
Anorexia/weight loss
More severe irAEs can include:
Enterocolitis (inflammation of the intestines)
Hepatitis (inflammation of the liver)
Dermatitis (skin inflammation)
Neuropathy (nerve damage)
Endocrinopathy (hormone problems)
These irAEs can be severe or even fatal.
No surprise there. Many drugs cause problems with a complete blockade of a specific vital pathway. In the case of Ipilimumab it blocks CLTA-4. Cancer uses CLTA-4 on immune cells to evade detection by killer T-cells. But the main role of CTLA-4 is to protect normal cells from autoimmunity caused destruction. Leronlimab only downregulates CLTA-4. Not quite as effective as Ipilimumab but also not causing those rtpes of side effects.
(10)
(0)